drugset / Trial / NCT06342336
HS-IT101 Injection in the Treatment of Advanced Solid Tumors
Phase 1
Recruiting
44 enrolled
Qingdao Sino-Cell Biomedicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collabThe First Hospital of Jilin University · collabWest China Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced solid tumor.
Timeline
- Start
- 2024-01-18
- Primary completion
- 2026-03-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-IT101 | Cell therapy | 5e+09 cells | Intravenous |
| Subject | HS-IT101 | Cell therapy | 6e+10 cells | Intravenous |